Evidence map›Paper›PMID 26792570›Full record

ArticlePharmaceutical research2016

Sugar-Grafted Cyclodextrin Nanocarrier as a "Trojan Horse" for Potentiating Antibiotic Activity.

Min Li, Koon Gee Neoh, Liqun Xu, Liang Yuan, David Tai Leong, En-Tang Kang, Kim Lee Chua, Li Yang Hsu

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Broadly Defined Antibiotic Adjuvants forThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. New Weapons to Fight againstAntibiotics (Basel, Switzerland) · 2023
    Review
  6. Review
  7. Review
  8. Combatting Antibiotic Resistance Using Supramolecular Assemblies.Pharmaceuticals (Basel, Switzerland) · 2022
    Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Min LiDepartment of Chemical and Biomolecular Engineering, National University of Singapore, Kent Ridge,, Singapore, 117585, Singapore.
Koon Gee NeohDepartment of Chemical and Biomolecular Engineering, National University of Singapore, Kent Ridge,, Singapore, 117585, Singapore. chenkg@nus.edu.sg.
Liqun XuDepartment of Chemical and Biomolecular Engineering, National University of Singapore, Kent Ridge,, Singapore, 117585, Singapore.
Liang YuanDepartment of Chemical and Biomolecular Engineering, National University of Singapore, Kent Ridge,, Singapore, 117585, Singapore.
David Tai LeongDepartment of Chemical and Biomolecular Engineering, National University of Singapore, Kent Ridge,, Singapore, 117585, Singapore.
En-Tang KangDepartment of Chemical and Biomolecular Engineering, National University of Singapore, Kent Ridge,, Singapore, 117585, Singapore.
Kim Lee ChuaDepartment of Biochemistry, National University of Singapore, Kent Ridge,, Singapore, 117543, Singapore.
Li Yang HsuDepartment of Medicine, National University of Singapore, Kent Ridge, Singapore, 119228, Singapore.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe use of "Trojan Horse" nanocarriers for antibiotics to enhance the activity of antibiotics against susceptible and resistant bacteria is investigated.

methodsAntibiotic carriers (CD-MAN and CD-GLU) are prepared from β-cyclodextrin grafted with sugar molecules (D-mannose and D-glucose, respectively) via azide-alkyne click reaction. The sugar molecules serve as a chemoattractant enticing the bacteria to take in higher amounts of the antibiotic, resulting in rapid killing of the bacteria.

resultsThree types of hydrophobic antibiotics, erythromycin, rifampicin and ciprofloxacin, are used as model drugs and loaded into the carriers. The minimum inhibitory concentration of the antibiotics in the CD-MAN-antibiotic and CD-GLU-antibiotic complexes for Gram-negative Escherichia coli, Pseudomonas aeruginosa and Acinetobacter baumannii strains, and a number of Gram-positive Staphylococcus aureus strains, including the methicillin-resistant strains (MRSA), are reduced by a factor ranging from 3 to >100. The CD-MAN-antibiotic complex is also able to prolong the stability of the loaded antibiotic and inhibit development of intrinsic antibiotic resistance in the bacteria.

conclusionsThese non-cytotoxic sugar-modfied nanocarriers can potentiate the activity of existing antibiotics, especially against multidrug-resistant bacteria, which is highly advantageous in view of the paucity of new antibiotics in the pipeline.

Indexed as

Acinetobacter baumanniiAnti-Bacterial AgentsBacteriaBacterial Infectionsbeta-CyclodextrinsCiprofloxacinClick ChemistryDrug CarriersDrug Resistance, BacterialErythromycinGlucoseHumansMannoseMicrobial Sensitivity TestsRifampinStaphylococcus aureusAnti-Bacterial Agentsbeta-CyclodextrinsbetadexCiprofloxacinDrug CarriersErythromycinGlucoseMannoseRifampinantibacterialantibiotic nanocarrierglucosemannoseβ-cyclodextrin

Identifiers

PMID26792570

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.